Long Noncoding RNA Serve as a Potential Predictive Biomarker for Breast Cancer: A Meta-Analysis

Table 2

Subgroup analysis of the diagnostic efficacy of lncRNA in breast cancer.

Parameter	No. of studies	No. of patients	AUC	Sensitivity	Specificity	Heterogeneity	Meta-regression ( value)
Ethnicity							0.186
Asian	35	4901	0.85 [0.81-0.87]	0.76 [0.71-0.80]	0.81 [0.75-0.85]	99%; 0.000
Caucasian	11	1242	0.75 [0.71-0.78]	0.67 [0.49-0.80]	0.72 [0.52-0.86]	99%; 0.000
Pathologic types							0.428
BC	36	4873	0.81 [0.77-0.84]	0.73 [0.66-0.78]	0.78 [0.70-0.84]	100%; 0.000
TNBC	10	1270	0.87 [0.84-0.90]	0.78 [0.70-0.84]	0.83 [0.78-0.87]	73; 0.013
Specimen							0.157
Tissue	14	1682	0.73 [0.69-0.77]	0.65 [0.52-0.76]	0.71 [0.57-0.83]	99%; 0.000
Plasma	17	2560	0.86 [0.82-0.89]	0.76 [0.70-0.81]	0.85 [0.77-0.90]	98%; 0.000
Serum	12	1679	0.86 [0.83-0.89]	0.78 [0.70-0.85]	0.80 [0.70-0.87]	98%; 0.000
Dysregulated state							0.070
Upregulated	38	5193	0.84 [0.81-0.87]	0.76 [0.72-0.80]	0.81 [0.75-0.85]	99%; 0.000
Downregulated	8	950	0.70 [0.65-0.73]	0.61 [0.40-0.78]	0.70 [0.44-0.87]	99%; 0.000
lncRNA							0.296
MALAT1	10	1670	0.88 [0.85-0.90]	0.81 [0.71-0.88]	0.81 [0.68-0.90]	98%; 0.000
H19	5	428	0.73 [0.69-0.77]	0.69 [0.63-0.75]	0.75 [0.65-0.83]	0; 0.242
HOTAIR	4	684	0.82 [0.78-0.85]	0.78 [0.73-0.82]	0.85 [0.72-0.93]	89%; 0.000